Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
← catalyst calendarNCT06750289 · readout in 807 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
400estimated
Sites
160
Countries
Bulgaria, Canada, China +10
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-28 | actual | When the study began enrolling |
| Primary completion | 2028-11-03 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-11-03 | estimated | The whole study's end, after follow-up |
| First posted | 2024-12-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Eosinophilic Asthma
Interventions
- Combination product: ICS-LABA
- Combination product: benralizumab
- Combination product: Placebo for Benralizumab
Primary outcome
what the primary-completion date above is the date OFAnnualized asthma exacerbation rate
measured Baseline through Week 48
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed